Vestibular migraine (VM) has been recognized a distinct subtype of migraine that causes
dizziness as the predominant symptom. Criteria for diagnosis have been adopted by the Barany
Society. Previous epidemiological research from the investigators has shown that VM affects
2.7% of the adult population of the United States. Yet, despite its high prevalence, there is
very little data upon which to guide treatment decisions. A Cochrane review in 2015 concluded
that there were no placebo controlled trials in VM, and none have been done since then. The
investigators recently developed and validated a patient reported outcome tool for VM called
VM-PATHI (VM- Patient Assessment Tool and Handicap Inventory). Anecdotal evidence suggests
that CGRP antagonists, such as Galcanezumab, may be effective in reducing or eliminating
symptoms in VM. Therefore, the investigators propose a pilot study of changes in VM-PATHI
scores, comparing active treatment (Galcanezumab) to placebo arms.